Publication Name	World Journal of Gastroenterology
Manuscript ID	9645
Country	Germany

Received	2014-02-22 11:46
Peer-Review Started	2014-02-22 13:18
First Decision by Editorial Office Director
Return for Revision	2014-03-31 10:11
Revised	2014-06-07 00:00
Publication Fee Transferred
Second Decision by Editor	2014-06-26 16:48
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2014-06-26 17:44
Articles in Press	2014-06-26 18:00
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-10-20 20:22
Publish the Manuscript Online	2014-10-29 19:34

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Surgery
Manuscript Type	Autobiography
Article Title	Gut-liver axis improves with meloxicam treatment after cirrhotic liver resection
Manuscript Source	Unsolicited Manuscript
All Author List	Astrit R Hamza, Avdyl S Krasniqi, Pramod Kadaba Srinivasan, Mamdouh Afify, Christian Bleilevens, Uwe Klinge and René H Tolba
Funding Agency and Grant Number
Corresponding Author	René H Tolba, MD, PhD, Professor, Director, Institute for Laboratory Animal Science and Experimental Surgery, University Hospital Rheinisch-Westfälische Technische Hochschule Aachen, Pauwelsstraße 30, 52074 Aachen, Germany. rtolba@ukaachen.de
Key Words	Liver cirrhosis; Liver resection; Gut-liver axis; Meloxicam; Cyclooxigenase-2; Microcirculation
Core Tip	Cyclooxygenase-2 (COX-2) inhibitors have been used in liver cirrhosis (LC), suppressing inflammation and liver fibrosis. However, the effects of COX-2 inhibition on the gut-liver axis after cirrhotic liver resection was not investigated previously. For the first time it can be concluded that one single dose of meloxicam administered 15 min prior to a 50% hepatectomy in LC, alleviates impairment of many functions of the gut-liver axis such as microcirculation, hepatocyte and enterocyte regeneration rate, and gastrointestinal transit, enabling better function and integrity of the remaining liver and the small bowel.
Publish Date	2014-10-29 19:34
Citation	Hamza AR, Krasniqi AS, Srinivasan PK, Afify M, Bleilevens C, Klinge U, Tolba RH. Gut-liver axis improves with meloxicam treatment after cirrhotic liver resection. World J Gastroenterol 2014; 20(40): 14841-14854
URL	http://www.wjgnet.com/1007-9327/full/v20/i40/14841.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i40.14841

Full Article (PDF)	WJG-20-14841.pdf
Full Article (Word)	WJG-20-14841.doc
Manuscript File	9645-Review.docx
Answering Reviewers	9645-Answering reviewers.pdf
Biostatistics Review Certificate	Biostatistician_Review_Report_20140222062155.pdf
Copyright License Agreement	9645-Copyright assignment.pdf
Institutional Review Board Approval Form or Document	Ethics_Committee_20140222062133.pdf
Peer-review Report	9645-Peer review.pdf
Scientific Misconduct Check	9645-CrossCheck.jpg
Scientific Editor Work List	9645-Scientific editor work list.pdf